Mecobalamin

Summary

Mecobalamin (CHEMBL2359370) is an approved small molecule (ATC B03BA05); indicated across 6 conditions including anemia and hand-foot syndrome.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: B03BA05
• Indications: 6 conditions
• Clinical trials: 16

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2359370
Name	Mecobalamin
Type	Small molecule
Max phase	4
ATC	B03BA05

Also known as: Asimil b-12, B-max, Mecobalamin, Mecobalamina, Mecobalamine, SID144206526, MECOBALAMIN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
anemia	4	MONDO:0002280	EFO:0004272
hand-foot syndrome	3	MONDO:0700048	EFO:1001893
vitamin B12 deficiency	2	MONDO:0020696	EFO:0000734
amyotrophic lateral sclerosis	2	MONDO:0004976	MONDO:0004976
type 2 diabetes mellitus	2	MONDO:0005148	MONDO:0005148
fibromyalgia	1	MONDO:0005546	EFO:0005687

Clinical trials

Total trials: 16.

Phase distribution

Phase	Trials
PHASE4	4
PHASE2	3
Not specified	3
PHASE2/PHASE3	2
PHASE3	2
PHASE1/PHASE2	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07133438	PHASE4	RECRUITING	Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment
NCT00165711	PHASE4	COMPLETED	The Role of Methycobalamin in Early Dementia Patients With Vitamin B12 Deficiency and Hyperhomocysteinaemia.
NCT05184049	PHASE4	UNKNOWN	Effects of Epalrestat on Peripheral Neuropathy and Central Nervous System in Diabetic Patients
NCT06220929	PHASE4	UNKNOWN	Mecobalamin Combined With Ceftriaxone Sodium in the Treatment of Sepsis Liver Injury
NCT07274696	PHASE3	NOT_YET_RECRUITING	Mecobalamin in Promoting Recurrent Laryngeal Nerve Function Recovery After Thyroid Surgery
NCT07423390	PHASE3	RECRUITING	Study on the Efficacy and Safety of Mecobalamin in Preventing Taxane-related Peripheral Neuropathy
NCT03167918	PHASE2/PHASE3	COMPLETED	Lung Function in Patients With Early Type 2 Diabetes Mellitus
NCT03593304	PHASE2/PHASE3	COMPLETED	Evaluate the Neuroprotective Effect of Vitamin B6 and Vitamin B12 Against Vincristine Induced Neurotoxicity in Acute Lymphoblastic Leukaemia Patients
NCT06813274	PHASE2	NOT_YET_RECRUITING	Multicenter RCT of Eye-Brain Imaging in Diabetes Neurovascular Coupling
NCT00699478	PHASE2	COMPLETED	Oral Vitamin B12 Administration for Vitamin B12 Deficiency After Total Gastrectomy
NCT03968042	PHASE2	UNKNOWN	Efficacy and Safety of Nerve Growth Factor or Edaravone on Alcohol-induced Brain Injury
NCT05008042	PHASE1/PHASE2	COMPLETED	Evaluation of the Efficiacy of Mecobalamine in the Treatment of Long-term Pain in Women Diagnosed With Fibromyalgia
NCT02853942	EARLY_PHASE1	UNKNOWN	Autologous Adipose Mesenchymal Stem Cell Transplantation in the Treatment of Patients With Hemifacial Spasm
NCT03983200	Not specified	UNKNOWN	Effect of Rotating Magnetic Therapy on Diabetic Peripheral Neuropathy
NCT04800666	Not specified	COMPLETED	Effect of Stellate Ganglion Block Combined With Facial Nerve Block on the Treatment of Idiopathic Facial Paralysis
NCT05623384	Not specified	UNKNOWN	Effect of Ultrasound-guided Stellate Ganglion Block Combined With Facial Nerve and Glossopharyngeal Nerve Block on the Treatment of Sudden Deafness

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).